RDHL logo

REDHILL BIOPHARMA LTD-SP ADR

RDHLNASDAQ
๐Ÿ† #5095 by market capUS Equity
โ€”โ€”
Quote unavailable
๐Ÿ””
Track RDHL
Get earnings, price moves & breaking news on Telegram
Track
24hโ€”
7dโ€”
14dโ€”
30dโ€”
ytdโ€”
1yโ€”
๐ŸฆMarket Cap
$3M
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
-97.6%
Declining
๐Ÿ“ŠGross Margin
60.4%
High
๐Ÿ’ตFCF Margin
โ€”
โš–๏ธP/S Ratio
0.7x
Cheap
Otter Score
โ€”
Insufficient data
No chart data available for RDHL.

Trading Snapshot

Day Range
โ€”
52-Week Range
$0.28 โ€“ $1.60
Volume (shares)
โ€”
Avg Volume (shares)
โ€”
Shares Outstanding
88.88B
Next Earnings
โ€”

Fundamentals Snapshot

Annual Revenue
$286,000
Last Q Revenue
โ€”
P/E Ratio
โ€”
P/S Ratio
0.7x
EPS (TTM)
$-0.00
Dividend Yield
โ€”
RDHL logo

REDHILL BIOPHARMA LTD-SP ADR

RDHL
Financial Trends

Financial history unavailable.

StockOtter ยท stockotter.space

About REDHILL BIOPHARMA LTD-SP ADR

RedHill Biopharma Ltd. is a specialized pharmaceutical firm concentrating its efforts mainly on therapies for digestive tract conditions and various infections. The company markets several gastrointestinal medications: Movantik, which addresses opioid-induced constipation in adults experiencing chronic non-cancer pain; Talicia, used to treat Helicobacter pylori infections in adult patients; and Aemcolo, prescribed for adults suffering from travelers' diarrhea. Its robust late-stage clinical pipeline features several promising investigational compounds. RHB-204 is currently in Phase 3 for pulmonary nontuberculous mycobacteria infections. Opaganib (Yeliva), an SK2 selective inhibitor, has completed Phase 2 for severe SARS-CoV-2 related COVID-19 pneumonia, is in Phase 2 for advanced unresectable cholangiocarcinoma, and is also being investigated in a researcher-sponsored Phase 2 study for prostate cancer. RHB-107 is progressing through Phase 2/3 trials for COVID-19 outpatients, is undergoing preclinical evaluation for advanced unresectable cholangiocarcinoma, and has successfully concluded Phase 2 studies for gastrointestinal and other solid tumors. Furthermore, RHB-104 is in Phase 3 development for Crohn's disease. RHB-102 (Bekinda) is also in Phase 3 for acute gastroenteritis and gastritis, following its successful completion of Phase 2 for irritable bowel syndrome with diarrhea. Lastly, RHB-106, an encapsulated formulation designed for bowel preparation, is preparing to commence Phase 2/3 clinical studies. Established in 2009, RedHill Biopharma Ltd. maintains its headquarters in Tel Aviv, Israel.

๐Ÿฆฆ

Otter Score Breakdown

How it's scoredFive components, each rated 1โ€“5โ˜… and equally weighted (20%), averaged to a 0โ€“100 score:๐Ÿ’Ž Quality โ€” gross margin๐Ÿš€ Growth โ€” revenue YoYโš–๏ธ Valuation โ€” P/S ratioโšก Momentum โ€” 30-day price change๐Ÿ’ง Dilution โ€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Insufficient data
โ€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.